SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001104659-21-046697
Filing Date
2021-04-05
Accepted
2021-04-05 19:00:42
Documents
2
Period of Report
2021-04-01

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm2111402d1_3.html 3  
1 OWNERSHIP DOCUMENT tm2111402d1_3.xml 3 1635
2 EXHIBIT 24.1 tm2111402d1_ex24-1.htm EX-24.1 7964
  Complete submission text file 0001104659-21-046697.txt   11086
Mailing Address 10 HUDSON YARDS, 37TH FLOOR New York NY 10001
Business Address 10 HUDSON YARDS, 37TH FLOOR NEW YORK NY 10001 646-747-1000
INTERCEPT PHARMACEUTICALS, INC. (Issuer) CIK: 0001270073 (see all company filings)

IRS No.: 223868459 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Business Address
ROSA-BJORKESON DAGMAR (Reporting) CIK: 0001643934 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-35668 | Film No.: 21807379